English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 2 February 2018, 16:15 HKT/SGT
Share:
    

Source: Vetter Pharma International GmbH
Vetter invites South Korea's pharma and biotech community to meet company management

SONGDO and RAVENSBURG, Feb 2, 2018 - (Media OutReach) - In an event at its new branch office attended by key customers and business associates, Vetter's senior management representatives presented the company's service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region. In addition, attendees were introduced to Mr. Michael Yi who will manage the office in his role as Business Development Manager for Vetter Pharma International GmbH, South Korea. Mr. Yi, who is based in Songdo, has pharmaceutical experience in responsible business development roles at several companies. He reports to Ms. Chervee Ho in her role as Director Key Account Management Asia Pacific.

During Vetter's customer event in the new branch office: Jong Hyun Kim, Director Supply Chain Management Department at Celltrion, Inc. (3rd from left) with Vetter's Chervee Ho, Peter Soelkner, Michael Yi and Oskar Gold (from left to right). (Picture source: Vetter Pharma International GmbH)

A rapidly growing local economy, combined with a regulatory environment conducive to the industry is a strong incentive for doing business in the country. And, because the population is aging rapidly with corresponding needs for adequate medication, South Korea demonstrates strong commitment to the pharmaceutical market through investing and supporting campaigns in R&D that contribute to innovative healthcare products. With its branch office, Vetter is well positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

"As a leading contract and development manufacturing organization in prefilled drug delivery systems with a vast amount of experience in business development, we are well aware that being physically close to our customers and their ongoing projects is one of the keys to good client relationships," said Vetter Managing Director Peter Soelkner. "Our event today acts as an additional signal of our strategy to build on our local presence and activities in this market," highlights Oskar Gold, Vetter's Senior Vice President Key Account Management, Marketing/Corporate Communications and Customer Project Management.

"Vetter's entry into the Korean pharmaceutical market represents an important recognition of the progress our nation has made in this segment," said Javier Camposano, Celltrion's Managing Director for Drug Product. "South Korean companies such as ours are in need of the services Vetter offers, to help us bring our innovative products to local and global markets. With its long history of qualitative resources, combined with its state-of-the art technology, Vetter can support us in competing on a level playing field and achieving our goals on a global scale. We wish Vetter a successful future in Korea."

Find the Vetter press kit, additional press releases, high-resolution pictures and more background information in our Download Center. https://www.vetter-pharma.com/en/news-events/download-center

About Vetter
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. The company has long-term experience offering services ranging from early development support including clinical manufacturing, to commercial supply and various packaging solutions for vials, syringes and cartridges. Vetter's customers range from small and midsize to the world's top 20 pharmaceutical and biotech companies. As a leading solution provider, the CDMO recognizes its responsibility in supporting the needs of its customers in developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Learn more about Vetter at www.vetter-pharma.com.

Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com

Topic: Press release summary
Source: Vetter Pharma International GmbH


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Wallace MacDonald Holdings (WMH) Ignites a New Era of American Manufacturing with Revolutionary "Made in America" Technology Complex in Nevada  
May 7, 2025 16:00 HKT/SGT
WIKA Reduces Debt by Rp1.47 Trillion, Improves Bond Rating in Q1-2025  
May 7, 2025 10:00 HKT/SGT
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D  
May 6, 2025 20:00 HKT/SGT
OMP Achieves Top Two Rankings in Four Use Cases in the 2025 Gartner Critical Capabilities for Supply Chain Planning Solutions Report  
May 6, 2025 17:00 HKT/SGT
WIKA Wins Two Prestigious ESG Awards for Commitment to Sustainability and Social Responsibility  
May 6, 2025 12:00 HKT/SGT
Eastern River Pty Ltd Marks Major Milestone with Appointment of Tom Paras as Managing Director - Head of Fund Investments  
May 6, 2025 09:30 HKT/SGT
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards  
May 5, 2025 19:30 HKT/SGT
New Database of Materials Accelerates Electronics Innovation  
May 5, 2025 03:20 HKT/SGT
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition  
Saturday, May 3, 2025 2:00:00 AM
TOYOTA GAZOO Racing Set for Spa spectacle  
Friday, May 2, 2025 6:29:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575